Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transcend FL
2019-004081-18Phase 2Unknown
- Sponsor
- Celgene Corporation
- Start
- Feb 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lisocabtagene maraleucel in follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL) and mature B-cell lymphoma, sponsored by Celgene Corporation. Primary endpoint: Complete response rate. Status: unknown.
02
Drugs
lisocabtagene maraleucel
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2019-004081-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004081-18.